Joon Bum Kim

Quick facts

Marketed products

• Vitamin K antagonist(warfarin) · Cardiovascular
  Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and blood clot formation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Joon Bum Kim portfolio CI brief
• Joon Bum Kim pipeline updates RSS